Xinyi Huang | Obesity | Best Researcher Award

Published on by Cardiology and Cardiovascular Medicine

Dr. Xinyi Huang | Obesity | Best Researcher Award

Gaozhou people's hospital | China

Author Profile:

Orcid

🌟 DR. XINYI HUANG: A DEDICATED PHYSICIAN AND CARDIOVASCULAR RESEARCHER

🎓 EARLY ACADEMIC PURSUITS

Dr. Xinyi Huang began her medical journey at Guangdong Medical University, where she pursued a Bachelor of Medicine in Anesthesiology from 2015 to 2020. During her undergraduate years, she displayed exceptional academic prowess and leadership abilities. She actively participated in academic competitions, earning several accolades such as the Excellence Award in the 4th National Undergraduate Anesthesiology Knowledge Competition and multiple school-level awards in anesthesiology imaging professional skill contests.

Her strong academic foundation led her to further her studies at Sun Yat-sen University, one of China’s leading medical institutions. There, she specialized in Internal Medicine (Cardiovascular Medicine) and completed her Master of Medicine at Sun Yat-sen Memorial Hospital between 2020 and 2023.

🏥 PROFESSIONAL ENDEAVORS

Dr. Huang’s clinical career commenced as a Resident Doctor at Sun Yat-sen University, where she honed her expertise in cardiovascular medicine. Following this, she joined Gaozhou People's Hospital in Guangdong in October 2024, where she currently serves in the Cardiovascular Department.

Her clinical work focuses on the diagnosis and management of atrial fibrillation, obesity-related cardiovascular risks, and other complex cardiovascular conditions, reflecting her research interests.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON OBESITY

Dr. Huang has actively contributed to the growing body of cardiovascular research. Her primary research areas include Atrial Fibrillation, particularly in patients with obesity and heart failure with preserved ejection fraction (HFpEF). She has co-authored significant academic papers addressing the association between body mass index (BMI), abdominal obesity, and the incidence of atrial fibrillation in heart failure patients.

Her research extends to exploring lipoprotein subgroups, such as HDL subtypes, and their influence on vascular inflammation in hypertensive patients, highlighting her multidisciplinary approach linking metabolism and cardiovascular health.

🌍 IMPACT AND INFLUENCE

Dr. Huang’s work contributes meaningfully to understanding how obesity and metabolic factors drive cardiovascular conditions like atrial fibrillation. Her research has been published in reputable journals such as Current Medical Research and Opinion and the Chinese Journal of Arteriosclerosis, enhancing clinical insights into cardiovascular disease prevention and management.

Her awards in anesthesiology and cardiovascular studies, along with her leadership roles and volunteer contributions, demonstrate her dedication to advancing both medical practice and community health.

📚 ACADEMIC CITES

Key Publications:

  1. Huang X, et al. “Association of Body Mass Index and Abdominal Obesity with Incidence of Atrial Fibrillation in Heart Failure with Preserved Ejection Fraction.” Current Medical Research and Opinion, 2025.

  2. Huang Jingjing, Huang Xinyi, et al. “Distribution of HDL Subgroups in Patients with H-type Hypertension and Its Impact on the Anti-inflammatory Function of Endothelial Cells.” Chinese Journal of Arteriosclerosis, 2023.

These publications are frequently cited by researchers exploring the links between metabolic dysfunction, arrhythmias, and cardiovascular inflammation.

🏅 AWARDS AND HONORS

  • Excellence Award, 4th National Undergraduate Anesthesiology Knowledge Competition (2018)

  • First Prize, Anesthesiology Imaging Professional Skills Competition Finals (2018)

  • Moral and Ethical Scholarship, Guangdong Medical University (2019)

  • Excellent Student Cadre, Guangdong Medical University (2017-2019)

  • Third-class Scholarship, Sun Yat-sen University (2020-2022)

  • Multiple awards recognizing her volunteerism, refereeing, and leadership contributions.

🌱 LEGACY AND FUTURE CONTRIBUTIONS

Looking ahead, Dr. Huang aspires to advance clinical strategies for obesity management in cardiovascular care, aiming to reduce the global burden of atrial fibrillation. She also seeks to explore AI-driven statistical tools and big data analytics to better predict cardiovascular outcomes.

With a strong passion for photography and life documentation, she continues to balance her rigorous scientific career with creative pursuits, inspiring a holistic approach to well-being and professional fulfillment.

📑 NOTABLE PUBLICATION

"Association of Body Mass Index and Abdominal Obesity with Incidence of Atrial Fibrillation in Heart Failure with Preserved Ejection Fraction"

Authors: Xinyi Huang; Xiao Liu; Yuan Jiang; Zhengyu Cao; Maoxiong Wu; Zhiteng Chen; Runlu Sun; Peng Yu; Jianyong Ma; Wengen Zhu
Journal: Current Medicinal Chemistry
Year: 2025

 

Zhuofeng Lin | Myocardial infarction | Best Researcher Award

Published on by Cardiology and Cardiovascular Medicine

Prof. Dr. Zhuofeng Lin | Myocardial infarction | Best Researcher Award 

Prof. Dr. Zhuofeng Lin, Guangdong Medical University, China

Prof. Dr. Zhuofeng Lin is the Dean of the Experimental Animal Center and Dean of the Innovational Center of Cardiometabolic Disease at Guangdong Medical University, China. His research focuses on cross-organ communication in cardiovascular and metabolic diseases, particularly the role of metabolic hormones and obesity. He has made significant contributions to understanding FGF21 metabolic regulation, impacting blood glucose stability, blood pressure control, and anti-atherosclerosis therapies. His work also explores new targets for anti-myocardial infarction, heart failure, and vascular calcification drugs, driving innovation in metabolic and cardiovascular medicine. His research is widely recognized in international medical science.

AUTHOR PROFILE

Google Scholar Profile

🎓EARLY ACADEMIC PURSUITS:

Prof. Dr. Zhuofeng Lin’s academic journey began with a strong foundation in medical sciences, focusing on cardiovascular and metabolic diseases. His early research explored physiological mechanisms and metabolic interactions, leading him to specialize in cross-organ communication and metabolic regulation. His education and initial training laid the groundwork for his extensive contributions to cardiometabolic research.

🏢PROFESSIONAL ENDEAVORS:

Prof. Lin has held prestigious positions at Guangdong Medical University, where he currently serves as:

  • Dean of the Experimental Animal Center 🐁
  • Dean of the Innovational Center of Cardiometabolic Disease 🫀

His leadership in these institutions has driven significant advancements in experimental research methodologies and the development of innovative treatment strategies for metabolic disorders.

🔍CONTRIBUTIONS AND RESEARCH FOCUS ON MYOCARDIAL INFARCTION:

Prof. Lin’s research is dedicated to practical applications, with a strong emphasis on:

  • Cross-organ communication in cardiovascular and metabolic diseases
  • Pathogenesis of cardiometabolic disorders linked to metabolic hormones and obesity
  • Fibroblast Growth Factor 21 (FGF21) and its role in metabolic regulation

His studies have provided groundbreaking insights into FGF21’s ability to regulate:
✅ Blood glucose levels
✅ Blood pressure stability
✅ Anti-atherosclerosis mechanisms
✅ Anti-Metabolic Dysfunction-Associated Steatohepatitis (MASH) therapies

Additionally, his work focuses on discovering new therapeutic targets for:
⚕️ Anti-myocardial infarction drugs
⚕️ Anti-heart failure treatments
⚕️ Anti-vascular calcification solutions

🌍IMPACT AND INFLUENCE:

Prof. Lin’s research has had a profound impact on global medical science, particularly in the fields of:
🔹 Metabolic disease management
🔹 Cardiovascular treatment innovations
🔹 Therapeutic drug development

His studies have influenced clinical practices, contributing to better patient outcomes in cardiovascular and metabolic health. His pioneering work in hormonal regulation and metabolic stability has inspired numerous scientists and researchers worldwide.

📄ACADEMIC CITES AND RECOGNITION:

Prof. Lin’s research is widely recognized in high-impact medical journals, with numerous citations supporting his theories. His work on FGF21 metabolic regulation is frequently referenced in the fields of endocrinology, cardiology, and metabolic research. He has been a keynote speaker at international medical conferences, sharing his insights with the global scientific community.

🚀LEGACY AND FUTURE CONTRIBUTIONS:

With an unwavering commitment to scientific innovation, Prof. Lin continues to shape the future of medical research. His ongoing projects aim to:
🔬 Develop novel cardiometabolic therapies
🔬 Enhance cross-organ communication research
🔬 Introduce cutting-edge treatments for heart disease and metabolic disorders

His legacy will be defined by his transformative contributions to medicine, paving the way for future breakthroughs in cardiovascular and metabolic health.

💡CONCLUSION:

Prof. Dr. Zhuofeng Lin is a pioneering leader in cardiometabolic research, making groundbreaking contributions to understanding metabolic regulation and cardiovascular health. His work on FGF21 has revolutionized approaches to blood glucose stability, blood pressure control, and anti-atherosclerosis treatments . With a vision for therapeutic innovation, he continues to explore new drug targets for heart failure, myocardial infarction, and vascular calcification . His impact on medical science is profound, shaping the future of metabolic and cardiovascular treatments. His dedication ensures lasting advancements in healthcare and patient well-being.

TOP NOTABLE PUBLICATIONS

Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice

Authors: Z Lin, H Tian, KSL Lam, S Lin, RCL Hoo, M Konishi, N Itoh, Y Wang, …
Journal: Cell Metabolism
Year: 2013

Fibroblast growth factor 21 prevents atherosclerosis by suppression of hepatic sterol regulatory element-binding protein-2 and induction of adiponectin in mice

Authors: Z Lin, X Pan, F Wu, D Ye, Y Zhang, Y Wang, L Jin, Q Lian, Y Huang, …
Journal: Circulation
Year: 2015

Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile

Authors: Z Lin, Z Wu, X Yin, Y Liu, X Yan, S Lin, J Xiao, X Wang, W Feng, X Li
Journal: PLoS One
Year: 2010

Exercise alleviates obesity-induced metabolic dysfunction via enhancing FGF21 sensitivity in adipose tissues

Authors: L Geng, B Liao, L Jin, Z Huang, CR Triggle, H Ding, J Zhang, Y Huang, …
Journal: Cell Reports
Year: 2019

Lipocalin-2 mediates non-alcoholic steatohepatitis by promoting neutrophil-macrophage crosstalk via the induction of CXCR2

Authors: D Ye, K Yang, S Zang, Z Lin, HT Chau, Y Wang, J Zhang, J Shi, A Xu, …
Journal: Journal of Hepatology
Year: 2016

Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese

Authors: Z Lin, Z Zhou, Y Liu, Q Gong, X Yan, J Xiao, X Wang, S Lin, W Feng, X Li
Journal: PLoS One
Year: 2011

FGF21 prevents angiotensin II-induced hypertension and vascular dysfunction by activation of ACE2/angiotensin-(1–7) axis in mice

Authors: X Pan, Y Shao, F Wu, Y Wang, R Xiong, J Zheng, H Tian, B Wang, …
Journal: Cell Metabolism
Year: 2018

Adiponectin protects against acetaminophen-induced mitochondrial dysfunction and acute liver injury by promoting autophagy in mice

Authors: Z Lin, F Wu, S Lin, X Pan, L Jin, T Lu, L Shi, Y Wang, A Xu, X Li
Journal: Journal of Hepatology
Year: 2014

Pancreatic fibroblast growth factor 21 protects against type 2 diabetes in mice by promoting insulin expression and secretion in a PI3K/Akt signaling‐dependent manner

Authors: Y Pan, B Wang, J Zheng, R Xiong, Z Fan, Y Ye, S Zhang, Q Li, F Gong, …
Journal: Journal of Cellular and Molecular Medicine
Year: 2019

Dynamic change of serum FGF21 levels in response to glucose challenge in human

Authors: Z Lin, Q Gong, C Wu, J Yu, T Lu, X Pan, S Lin, X Li
Journal: The Journal of Clinical Endocrinology & Metabolism
Year: 2012